News
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...
Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...
The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.
Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...
The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...
Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...
Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
6h
24/7 Wall St. on MSNI Am Buying 5 Blue-Chip Dividend Stocks That Have Been Crushed in 2025These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results